The researchers believe their findings could be used to change how patients' risk for breast cancer, colon cancer, or heart disease is calculated.
Yale School of Medicine researchers analyzed patients and families affected by early-onset coronary artery disease to uncover mutations in CELA2A.
Reuters reports that on the launch of Verve Therapeutics, a biotech focused on using gene editing to treat cardiovascular disease.
Gencove offers low-coverage whole-genome sequencing and has developed imputation algorithms and informatics to extract useful information from the data.
The firm is using collaborations to access the large, diverse cohorts it needs to support its goal of commercializing its SomaScan system as a clinical platform.
In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.
The partnership will allow people to see their genetic risk with other health data that Seqster pulls from electronic health records and wearables.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.
Researchers compared findings from genome-wide association studies for 62 traits or conditions with genes implicated in 20 Mendelian disorder types, uncovering new ties.
The company is collecting validation evidence it intends to submit to the FDA next year, which will also support launch of the test as an LDT.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.